Table 1

Baseline and procedural characteristics

CharacteristicsAll patients (n=915)Non-APT (n=716)APTP value*P value†
Total (n=199)SAPT (n=137)DAPT (n=62)
Age, mean+SD64 (55–72)64 (55–73)62 (55–69)62 (55–69)62 (57–69.25)0.0950.248
Male611 (66.8)465 (64.9)146 (73.4)97 (70.8)49 (79)0.0260.043
SBP, mean+SD147 (130–161)146 (130–160)148 (134–161)145 (132.5–161)151.5 (139.5–165.5)0.5930.197
Admission NIHSS, median (IQR)14 (9–20)14 (9–20)15 (10–20)15 (11–22)14 (4.75–18.25)0.9750.083
ASPECTS (anterior circulation only), median (IQR)8 (7–8)8 (7–8)8 (7–8)7 (7–8)8 (7–10)0.780.005
Vascular risk factors
 Atrial fibrillation164 (17.9)135 (18.9)29 (14.6)23 (16.8)6 (9.7)0.1640.182
 Diabetes mellitus145 (15.8)112 (15.6)33 (16.6)23 (16.8)10 (16.1)0.7480.943
 Previous stroke97 (10.6)75 (10.5)22 (11.1)12 (8.8)10 (16.1)0.8140.286
 Hypertension499 (54.5)378 (52.8)121 (60.8)80 (58.4)41 (66.1)0.0450.08
 Smoking311 (34)244 (34.1)67 (33.7)39 (28.5)28 (45.2)0.9140.07
 Drinking142 (15.5)109 (15.2)33 (16.6)23 (16.8)10 (16.1)0.6390.89
TOAST classification
 Large artery atherosclerosis649 (70.9)501(70)148 (74.4)102 (74.5)46 (74.2)0.2270.481
 Small perforator0 (0)
 Cardiogenic168 (18.4)138 (19.3)30 (15.1)22 (16.1)8 (12.9)0.1760.347
 Other aetiology10 (1.1)6 (0.8)4 (2)4 (2.9)0 (0)0.3070.094
 Unknown aetiology88 (9.6)71 (9.9)17 (8.5)9 (6.6)8 (12.9)0.5610.315
Occlusion site
 ICA266 (29.1)225 (31.4)62 (31.2)46 (33.6)16 (25.8)0.9420.548
 M1489 (53.4)267 (37.3)69 (34.7)45 (32.8)24 (38.7)0.4980.58
 M2/3160 (17.5)66 (9.2)18(9)9 (6.6)9 (14.5)0.9410.198
 ACA5 (0.5)3 (04)2 (1)2 (1.5)0 (0)0.3210.309
 PCA17 (1.9)16 (2.2)1 (0.5)0 (0)1 (1.6)0.1920.058
 BA93 (10.2)70 (9.8)23 (11.6)19 (13.9)4 (6.5)0.4620.217
 VA93 (10.2)69 (9.6)24 (12.1)16 (11.7)8 (12.9)0.3170.585
Anterior circulation stroke (n%)712 (77.8)561 (78.4)151 (75.9)102 (74.5)49(79)0.4580.586
Posterior circulation stroke (n%)203 (22.2)155 (21.6)48 (24.1)35 (25.5)13(21)0.4580.586
OTD time, median (IQR), min180 (105–297)180 (102.25–285)180 (120-300)180 (120–300)176 (88.75–332.5)0.550.822
DTP time, median (IQR), min110 (70–160)110 (70–160)115 (70–170)110 (76–155)126.5 (52.25–186.25)0.3860.62
PTR time, median (IQR), minn=911, 80 (50–112)80 (55–115)70 (44.25–110)78 (50–122.5)65 (30–90)0.0330.001
OTP time, median (IQR), min315 (220–440)310 (220–430)345 (201–460)340 (227–449.5)379.5 (180–491.25)0.250.508
OTR time, median (IQR), minn=911, 403 (300–540)400 (301.5–530)417.5 (300–562.5)406 (327.5–547.5)440 (242.5–602.5)0.4910.655
Periprocedural other antithrombotic and anticoagulant
 Bridging IVT241 (26.3)211 (29.5)30 (15.1)19 (13.9)11 (17.7)0.0000.000
 Tirofiban308 (33.7)197 (27.5)111 (55.8)80 (58.4)31 (50)0.0000.000
 Heparin during EVT367 (40.1)283 (39.5)84 (42.2)51 (37.2)33 (53.2)0.4940.081
Procedures characteristics
 General anaesthesia331 (36.2)239 (33.4)92 (46.2)67 (48.9)25 (40.3)0.0010.002
 MT stent retrieval645 (70.5)497 (69.4)148 (74.4)105 (76.6)43 (69.4)0.1750.231
 MT aspiration60 (6.6)31 (4.3)29 (14.6)21 (15.3)8 (12.9)0.0000.000
 Intra-arterial thrombolysis189 (20.7)162 (22.6)27 (13.6)16 (11.7)11 (17.7)0.0050.013
 Balloon angioplasty85 (9.3)66 (9.2)19 (9.5)17 (12.4)2 (3.2)0.8870.083
 Stent angioplasty134 (14.6)109 (15.2)25 (12.6)15 (10.9)10 (16.1)0.3480.407
  • Boldface type indicates statistical significant.

  • *P value between non-APT and APT group.

  • †P value between non-APT, SAPT and DAPT groups.

  • ACA, anterior cerebral artery; APT, antiplatelet; ASPECTS, Alberta Stroke Program Early CT score; BA, basilar artery; DAPT, dual antiplatelet; DTP, door-to-puncture; EVT, endovascular treatment; ICA, internal carotid artery; IVT, intravenous thrombolysis; M1, middle cerebral artery M1 segment; M2/3, middle cerebral artery M2/3 segment; NIHSS, National Institutes of Health Stroke Scale score; OTD, onset-to-door; OTP, onset-to-puncture; OTR, onset-to-recanalisation; PCA, posterior cerebral artery; PTR, puncture-to-recanalisation; SAPT, single antiplatelet; SBP, systolic blood pressure; TOAST, trial of ORG 10172 in acute stroke treatment; VA, vertebral artery.